Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.

Literature DB >> 10639386

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.

Y Kawakami¹, T Akahane, M Yamaguchi, K Oana, Y Takahashi, Y Okimura, T Okabe, A Gotoh, T Katsuyama.

Abstract

The MICs of rabeprazole sodium (RPZ), a newly developed benzimidazole proton pump inhibitor (PPI), against 133 clinical Helicobacter pylori strains revealed a higher degree of activity than the another two PPIs, lansoprazole and omeprazole. Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined. Moreover, no apparent antagonistic effect appeared among all of the strains tested.

Entities: Chemical Species

Mesh：

Substances：

Year: 2000 PMID： 10639386 PMCID： PMC89707 DOI： 10.1128/AAC.44.2.458-461.2000

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.

Authors: M L Cloud; N Enas; T J Humphries; S Bassion
Journal: Dig Dis Sci Date: 1998-05 Impact factor: 3.199

2. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors: B J Marshall; J R Warren
Journal: Lancet Date: 1984-06-16 Impact factor: 79.321

3. Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors: J R Warren; B Marshall
Journal: Lancet Date: 1983-06-04 Impact factor: 79.321

Review 4. Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept.

Authors: C S Goodwin
Journal: Lancet Date: 1988 Dec 24-31 Impact factor: 79.321

Review 5. Helicobacter pylori: current status.

Authors: D Y Graham; M F Go
Journal: Gastroenterology Date: 1993-07 Impact factor: 22.682

6. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.

Authors: A Gotoh; Y Kawakami; T Akamatsu; T Katsuyama
Journal: Microbiol Immunol Date: 1997 Impact factor: 1.955

7. Efficacy of lansoprazole in eradication of Helicobacter pylori.

Authors: T Takimoto; K Ido; Y Taniguchi; K Satoh; K Saifuku; K Kihira; Y Yoshida; K Kimura
Journal: J Clin Gastroenterol Date: 1995 Impact factor: 3.062

8. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.

Authors: M Hirai; T Azuma; S Ito; T Kato; Y Kohli
Journal: J Gastroenterol Date: 1995-08 Impact factor: 7.527

9. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori.

Authors: P Moayyedi; P Sahay; D S Tompkins; A T Axon
Journal: Eur J Gastroenterol Hepatol Date: 1995-09 Impact factor: 2.566

10. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.

Authors: M Tsuchiya; L Imamura; J B Park; K Kobashi
Journal: Biol Pharm Bull Date: 1995-08 Impact factor: 2.233

9 in total

Review 1. Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors: Javier P Gisbert
Journal: Drugs Date: 2005 Impact factor: 9.546

2. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

Authors: Jyh-Chin Yang; Chun-Jung Lin; Hong-Long Wang; Jin-De Chen; John Y Kao; Chia-Tung Shun; Chien-Wei Lu; Bor-Ru Lin; Ming-Jium Shieh; Ming-Chu Chang; Yu-Ting Chang; Shu-Chen Wei; Lin-Chih Lin; Wen-Chun Yeh; Jen-Shin Kuo; Chien-Chih Tung; Yew-Loong Leong; Teh-Hong Wang; Jau-Min Wong
Journal: Clin Gastroenterol Hepatol Date: 2014-11-14 Impact factor: 11.382

Review 3. Rabeprazole: an update of its use in acid-related disorders.

Authors: C I Carswell; K L Goa
Journal: Drugs Date: 2001 Impact factor: 9.546

Review 4. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors: Claudine M Baldwin; Susan J Keam
Journal: Drugs Date: 2009-07-09 Impact factor: 9.546

5. Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment.

Authors: Kyoichi Adachi; Tomoyuki Hashimoto; Shunji Ishihara; Hirofumi Fujishiro; Shuichi Sato; Hiroshi Sato; Yuji Amano; Shuzo Hattori; Yoshikazu Kinoshita
Journal: Curr Ther Res Clin Exp Date: 2003-07